Purchase Order 75N93024P01107

Award Date 9/30/24
Potential Completion Date 9/29/25
Potential Value $16K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $95,931 firm-fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc. for a MiSeq High Throughput Sequencer System. The award did not have a set-aside designation. The MiSeq system will be used in NIAID's Laboratory of Immunoregulation and must be fully compatible with Illumina's existing on-site software, kits, and reagents. Illumina has a history of providing...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of genetic sequencing systems and analytical instruments. The $7,902 contract is for comprehensive service and support for Illumina's MiSeq gene and small genome sequencer. The award has no set-aside designation and is not associated with a larger contract vehicle. Illumina has been awarded...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc. for the maintenance of an Illumina MiSeq sequencer used for immunology and inflammation research. The contract has a ceiling value of $16,198.00 and a period of performance through May 26, 2026. Illumina, a leading manufacturer of genetic sequencing and genomic analysis technologies, has been...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc. for an MISEQ2 automated DNA sequencing system. The $90,882 contract does not have a set-aside designation. Illumina is a manufacturer and provider of genetic analysis instruments and reagents, and has previously received awards from federal agencies like the NIH, CDC, USDA, and VA to support genomic...
This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Illumina, Inc. for the purchase of a MiSeq System sequencing platform. The contract has a ceiling value of $95,931.00 and a completion date of August 21, 2014. Illumina is a manufacturer of sequencing and genomic analysis instruments and reagents that has previously provided such products and services to various federal...
This is a firm fixed price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the prime contractor Illumina, Inc. for the purchase of MiSeq sequencing kits. The order, valued at $13,071, does not have a set-aside designation. Illumina is a for-profit manufacturer and provider of genetic sequencing and analysis instruments and reagents. The award supports NIAID's genomic research and diagnostics...
This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and consumables. The contract is for service and maintenance of an Illumina MiSeq system for fiscal year 2021, with a total ceiling value of $14,070.00. The contract has no set-aside designation. Illumina has received numerous prior federal...
This is a $119,060.18 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc. for the provision of an MISEQ2 sequencing instrument and associated reagents. The contract has no set-aside designation. Illumina, a manufacturer of genetic analysis instruments and reagents, has been awarded multiple prior federal contracts and sub-grants to provide...
This is a $16,198 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc. for a MiSeq Silver Support Plan with an ultimate completion date of February 5, 2026. Illumina is a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis, and has been awarded previous prime contracts and subcontracts by federal...
This is a $41,061.69 firm fixed-price purchase order awarded to Illumina, Inc. by the National Institute of Allergy and Infectious Diseases (NIAID) for a NEXTSEQ 500 and MISEQ service agreement. The contract has a period of performance through February 27, 2025. Illumina is a manufacturer of genetic sequencing instruments and reagents that has previously provided similar products and services to support genomic research and diagnostics across various federal agencies. This award does not...

This is a $16,127.00 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc. for a service agreement to maintain a MiSeq sequencing instrument. The award does not include any set-aside provisions. Illumina is a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The company has previously received other prime and subcontract awards from federal agencies like NIH, CDC, USDA, and VA to provide sequencing systems, reagents, and related services to support research and diagnostics. This MiSeq instrument maintenance service award will enable NIAID to continue leveraging Illumina's proprietary sequencing technology to support its mission of conducting and supporting research to understand, treat, and prevent infectious diseases.

Generated 9/6/24, 9:20 AM